Patent ID: 11885817
Assignee: COGNIZANCE BIOMARKERS, LLC
Field: Measurement (Instruments)
Classification: CPC G  A  C | IPC C  G

Claim 8:
9. A method of treating epilepsy in a patient having an decreased blood level of one or more biomarkers selected from the group consisting of: interleukin-16 (IL-16), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), tumor necrosis factor (TNF)-α, IL-5, tumor necrosis factor-beta (TNF-β), MCP-1, interleukin-10 (IL-10), MIP-1a, IL-12/IL-23p40, IL-17A, stem cell factor (SCF), IL-1a, macrophage derived chemokine (MDC), TNF-RII, Eotaxin-3, interferon-gamma (IFN-γ), IL-13, IL-2, IL-4, and IL-6; the method comprising administering to the patient one or more therapeutic agents selected from the group consisting of phenytoin, carbamazepine, lamotrigine, oxcarbazepine, zonisamide, and pharmaceutically acceptable salts and prodrugs thereof.